Esketamine | Wikipedia audio article
Channel: wikipedia tts
Date: 2018-12-10

This is an audio version of the Wikipedia Article:
Esketamine


00:01:11 1 Medical uses
00:01:49 2 Pharmacology
00:04:03 3 History
00:04:20 4 Society and culture
00:04:30 4.1 Generic names
00:04:57 4.2 Brand names
00:05:14 4.3 Availability
00:05:34 5 Research
00:05:43 5.1 Depression
00:06:42 6 See also



Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

You can find other Wikipedia audio articles too at:
https://www.youtube.com/channel/UCuKfABj2eGyjH3ntPxp4YeQ

You can upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts



"The only true wisdom is in knowing you know nothing."
- Socrates



SUMMARY
=======
Esketamine, also known as (S)-ketamine or S(+)-ketamine and sold under the brand names Ketanest and Ketanest S among others, is a general anesthetic and a dissociative hallucinogen. It is the S(+) enantiomer of ketamine, which is an anesthetic and dissociative similarly. It is given by intravenous infusion.Esketamine acts primarily as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It also acts to some extent as a dopamine reuptake inhibitor but, unlike ketamine, does not interact with the sigma receptors.Esketamine was introduced for medical use in 1997. In addition to its anesthetic effects, the medication shows properties of being a rapid-acting antidepressant, and is under development for use as such. As of November 2017, it has completed phase III clinical trials for treatment-resistant depression (TRD) in the United States, with results to be announced in the second quarter of 2018. Johnson & Johnson plans on filing a Food and Drug Administration (FDA) New Drug Application (NDA) for approval in 2018. Esketamine could be approved as soon as early 2019.